metabolized proportion of the dose increases to 50-70% in patients receiving enzyme-inducing AEDs (e.g. carbamazepine and phenytoin) [6] . Therefore, during concomitant treatment with topiramate and carbamazepine or phenytoin, topiramate clearance increases 2-fold and its half-life becomes shorter by up to 50%. This PK change may require topiramate dose adjustment when phenytoin or carbamazepine are added or discontinued [1] . However, these factors have not been thoroughly quantified, and remain controversial for non-enzyme-inducing or second-generation AEDs [7, 8] . Since topiramate is more commonly used for epilepsy treatment in polytherapy rather than in monotherapy, more information about the influence of co-medication on the PK properties of topiramate is needed. Therefore, the main objective of the present study was to identify the factors influencing topiramate PK in a large population of adult patients with epilepsy using population PK analysis.
Materials and methods

Patients
We collected 670 blood samples of 550 adult patients treated with topiramate with or without concomitant AEDs for epilepsy from February 2011 to May 2013 at the epilepsy center, Seoul National University Hospital, Seoul, Korea. Blood samples were drawn from each patient in a steady state. Data, including demographic characteristics, weight, height, age, and sex; results of biochemical analysis, serum creatinine, creatinine clearance, serum transaminases (aspartate transaminase [AST] and alanine transaminase [ALT]), total bilirubin, albumin and prothrombin time; concomitant drug therapy, dosing regimen, and times of blood sampling were collected from electronic medical charts. Written informed consent was obtained from all patients. The study was approved by the institutional review board of Seoul National University Hospital.
Determination of topiramate concentration
Plasma concentrations of topiramate were determined using positive ion liquid chromatography (LC) (Agilent 1100 series; Agilent Technologies, Wilmington, DE, USA)-tandem mass spectrometry (MS/MS) (API 4000TM instrument; Applied Biosystems/ MDS Sciex, Toronto, Canada). Chromatographic separation was performed at 30 8C using a Luna1 C18 column (50 Â 2.0 mm, 5 mm Phenomenex, Torrance, CA, USA) operated under reversephase conditions with a mobile phase A (10 mmol/L ammonium acetate:acetonitrile = 90:10, v/v) with 0.1% formic acid and mobile phase B (10 mmol/L ammonium acetate:methanol:acetonitrile = 10:45:45, v/v) with 0.1% formic acid. The standard curve for topiramate was linear in the range of 20-2,000 ng/mL. Intrabatch and inter-batch accuracy ranged from 89.11 to 99.48%, while the precision ranged from 2.70 to 6.54% at concentrations of 50, 500, and 1600 ng/mL.
Population PK model
A population PK analysis was conducted using the first-order conditional estimation method in NONMEM version 7.2 (Icon Development Solutions, Ellicott City, MD, USA) with the G77 Fortran compiler. The structural model of topiramate was assumed to follow a one-compartment model with first-order absorption and elimination (ADVAN2, TRANS2). Absorption rate constant (k a ) was fixed at 2 h À1 as the same method used in a previous report [8] . Apparent clearance (CL/F) and apparent volume of distribution (V/F) were estimated in the model development process.
Inter-individual variability (IIV) of PK parameters was evaluated using an exponential error model, and the PK parameters of the ith subject (P i ) were described as the following equation:
where u is the typical value of the PK parameters, and h i is a random variable of the ith subject. Additive, proportional, and combined (additive and proportional) error models were compared with assess residual variability. Model selection was based on the likelihood-ratio test, Akaike information criterion, and goodnessof-fit including the distribution of conditional weighted residuals vs. time after dose. A decrease in the objective function value (OFV) greater than 3.84 (a = 0.05, df = 1) between two nested models was considered significant.
Demographic and clinical variables tested as potential covariates were age, sex, body weight (WT), height, serum creatinine, creatinine clearance (CLcr), total bilirubin, prothrombin time, albumin, AST, ALT, daily dose (DOSE), and concomitant medica-
, and alprazolam). CLcr was estimated by the modification of diet in renal disease (MDRD) formula [9] and prothrombin time was expressed as an international normalized ratio. When a variable was missing in a patient, this value was replaced by the population median value. The covariate model was built in a stepwise fashion with forward selection and backward deletion. Each covariate was included to the base model one at a time in the forward selection based on previously described model selection criteria. The full covariate model was developed by incorporating all significant covariates. At the backward deletion step, covariates that did not increase the minimized OFV by more than 6.63 (a = 0.01, df = 1) were deleted from the full model.
Model evaluation
A bootstrap resampling method and visual predictive checks (VPCs) were used to evaluate the stability and robustness of the final PK model. The final PK model was fitted repeatedly to the 1,000 bootstrap-resampled data sets from the original data set. The median and 95% confidence intervals (CIs) of PK parameters obtained from the bootstrap process were compared with the final parameter estimates. VPCs were performed by simulating 1,000 data sets from the final model. The 5th, 50th, and 95th percentile curves of the simulated concentrations at each time were overlaid with observed concentrations classified by significant covariates.
Results
Characteristics of the patients
Baseline characteristics of the patients are summarized in Table 1 . All 550 patients (222 male) were included in the analysis. The mean age was 39.0 years (range 18-75 years) and the mean weight was 63.9 kg (range 27À128 kg). Median daily dose and plasma concentration of topiramate were 100 mg (range 25À1000 mg) and 3.2 mg/L (range 0.4À19.7 mg/L), respectively. Topiramate was used as monotherapy in 55 patients (10%). Otherwise, it was mostly used in polytherapy with multiple AEDs. The numbers of concomitant AEDs were one in 172 patients (31.3%), two in 145 (26.4%), three in 114 (20.7%), and four or more in 64 patients (11.6%). The five most frequently used concomitant AEDs were levetiracetam, CBZ, valproic acid, OXC, and lamotrigine, in that order. Table 2 . The median parameter estimates obtained from the bootstrap process were reasonably similar to the estimates obtained previously with the original data set. VPCs of the final PK model are presented in supplementary materials 1 and 2 (topiramate 200 and topiramate 100 mg, respectively) and stratified by concomitant medications.
Population PK model
Discussion
This study systematically analyzed the influence of various covariates on topiramate PK by a nonlinear mixed effects modeling approach in the largest group of patients ever reported to our knowledge. The covariate analysis showed that CLcr, DOSE, and comedication with PHT, CBZ, OXC, and PB were included as significant covariates on the CL/F. Population PK studies of topiramate use in epilepsy to guide the dosing regimen are limited. Population PK models can be important extensions of therapeutic drug monitoring because they allow estimation of individual PK parameters from a large number of patients, but based on a small number of sparsely measured drug concentrations in each patient [10] . In the present study, topiramate CL/F of a typical patient with CLcr of 90 mL/min and dose of 100 mg, was expected to be 1.16 L/h. This is a little lower, but comparable with the findings of previous studies that reported topiramate CL/F to be between approximately 1.2 and [8, 11, 12] . Our study population, which included patients with greater age, lower body weight, and lower daily doses compared with previous studies [8, 11] might have influenced the lower clearance. Topiramate CL/F was found to increase with cotreatment with PHT, CBZ, OXC, and PB. Topiramate CL/F was 117, 87, 55, and 41% higher in patients co-treated with PHT, CBZ, OXC, and PB, respectively, compared with patients on topiramate monotherapy. Co-medication is one of important contributors to PK variability. Drug interactions must be carefully considered when multiple drugs are prescribed [7] . Topiramate is more often given as an add-on therapy than as a monotherapy, therefore this PK interaction has particular significance for treatment with topiramate. Previous studies demonstrate that co-treatment with enzyme-inducing AEDs (CBZ, PHT, PB, and primidone) enhances hepatic metabolism of topiramate [1, 7, 8, 11, 13] . Although the specific cytochrome P450 isoenzymes for the metabolism of topiramate have not yet been identified, it seems evident that isoenzymes induced by carbamazepine and phenytoin play a major role [14] . Our results with CBZ, PHT, and PB are consistent with those of previous studies. Furthermore, our findings regarding OXC are worthy of notice. Although a few studies suggested that OXC induces the metabolism of and decreases the serum levels of topiramate [14, 15] , the impact of OXC on topiramate PK is less known and controversial. Our study showed that OXC is the only second-generation AED among the frequently used concomitant AEDs that can influence the clearance of topiramate. The impact of OXC on topiramate was greater than that of PB. On the other hand, valproic acid, lamotrigine, and levetiracetam have no significant effect on topiramate CL/F. This is consistent with the findings of some previous studies where lamotrigine and levetiracetam were not found to have any clinically significant influence on topiramate PK [1, 16, 17] . However, there have been some controversial reports about the impact of valproic acid on topiramate PK [7, 18, 19] . Unfortunately, we could not confirm those findings, and their clinical significance is uncertain. Nevertheless, careful precaution against adverse events is needed when topiramate is used with valproic acid, because topiramate can enhance the risk of valproic acid-induced adverse events, such as encephalopathy [20] , and other typical side effects [21] . Renal function (CLcr calculated by MDRD) demonstrated significant influence on topiramate CL/F in this study. This was expected, because topiramate is excreted predominantly unchanged through the kidneys [3] . Mean topiramate CL/F in patients with mild to moderate and severe renal impairment was reduced by 58 and 46%, respectively, compared with matching healthy participants [5] . Meanwhile, hepatic function (AST, ALT, total bilirubin, prothrombin time, and albumin) did not exert significant influence on topiramate CL/F in our study. Although topiramate is also eliminated by hepatic clearance via hydroxylation and hydrolysis metabolic pathways [22] , the clinical significance of hepatic function on topiramate clearance in monotherapy is low when compared with renal function.
L/h
Although the effect of DOSE was very small in the final model, it was identified as one of determining variables for topiramate CL/F. This suggests that CL/F increases marginally with the increase of DOSE. However, we could not specify a particular mechanism in this study.
There is a correlation between age and topiramate CL/F in populations of children and adults with epilepsy [4, 8, 13, 23] . However, we did not find a significant influence of age on topiramate CL/F. This is in part because our study population was composed of mainly adult patients. Previous studies showed a relationship between age and CL/F in children; however, the relationship was absent in patients older than 17 years [4, 17] . In addition, we used CLcr calculated by the MDRD formula, including a factor for age. Accordingly, age could probably influence topiramate CL/F via CLcr in an inverse correlation. Even so, we could not estimate the independent impact of age.
An important limitation of our study is the sparse sampling. However, population PK analysis helped to overcome this limitation because it does not require ''rich'' data (many observations/subject), as required for analysis of single-subject data, nor is there a need for structured sampling time schedules [24] .
In conclusion, the population PK analysis successfully described the clearance of topiramate in the adult patients with epilepsy in our study. This indicated that topiramate CL/F increased with comedication with PHT, CBZ, OXC, and PB. This population PK model can be helpful for individualizing the topiramate dosage regimen in a real clinical practice, especially for patients on polytherapy with PHT, CBZ, OXC, and PB.
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